Detalles de la búsqueda
1.
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
Cancer
; 130(3): 400-409, 2024 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37864520
2.
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Oncologist
; 29(4): e514-e525, 2024 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38297981
3.
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.
Oncologist
; 28(12): 1100-e1292, 2023 Dec 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37311055
4.
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
Gynecol Oncol
; 168: 76-82, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36423446
5.
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors.
Invest New Drugs
; 40(1): 99-105, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34468905
6.
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
Invest New Drugs
; 40(2): 290-299, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34562230
7.
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.
Invest New Drugs
; 40(1): 124-133, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34559346
8.
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies.
Br J Cancer
; 124(9): 1533-1539, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33674736
9.
Overview of Ocular Side Effects of Selinexor.
Oncologist
; 26(7): 619-623, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33728727
10.
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials.
Oncologist
; 26(7): 588-596, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33783054
11.
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 21(7): 957-968, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32553118
12.
Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings.
Oncologist
; 25(11): e1628-e1639, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32537847
13.
Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study.
J Med Internet Res
; 21(3): e10348, 2019 03 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-30869638
14.
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials.
Br J Cancer
; 118(6): 763-769, 2018 03 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29462132
15.
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.
Br J Cancer
; 118(11): 1419-1424, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29695765
16.
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept.
Invest New Drugs
; 36(4): 601-607, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29075985
17.
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.
Invest New Drugs
; 36(3): 416-423, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29047029
18.
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.
Invest New Drugs
; 36(4): 638-646, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29159766
19.
Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER.
Int J Cancer
; 140(1): 208-215, 2017 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27599876
20.
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.
Invest New Drugs
; 35(5): 616-626, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28194539